A pilot study of interferon alpha suppository treatment for chronic hepatitis C

A pilot study of interferon alpha suppository treatment for chronic hepatitis C - Interferon alpha suppository treatment for chronic hepatitis C

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001744

Enrollment

Registered

2009-03-21

Start date

1998-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

Lymphoblastoid interferon (1000IU) containing suppository Suppository matrix

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Positive for HCV RNA

Exclusion criteria

Exclusion criteria: Previous or present treatment with interferon, average daily intake of alcohol exceeding 50g of ethanol, choledocholithiasis, cirrhosis, autoimmune hepatitis, primary biliary cirrhosis, hepatitis B virus infection, human immunodeficiency virus infection, drug abuser, drug-related liver disease and pregnancy

Design outcomes

Primary

Measure	Time frame
Antiviral effect (decline of the viral load)	—

Secondary

Measure	Time frame
(1)Improvement of liver function (2)Adverse effect	—

Countries

Japan

Contacts

Public ContactYoshimichi Haruna

Osaka Prefectural General Medical Center Department of Gastroenterology and Hepatology

apple-123-grape@ab.auone-net.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026